Fig. 1.

The effect of ER antagonists, SERMs (a) and SERDs (b), on NFκB activity in ER+ breast cancer cells. MCF-7 cells were transfected with NFκB-RE and renilla reporter plasmids. Cells were then pretreated with various concentrations of drugs for 1 h, followed by TNFα (10 ng/mL) for 4 h to activate the NFκB pathway. Each drug’s inhibitory activity was calculated as percentage of TNFα alone, which is set to 100%. Data are presented as mean ± SEM